IngredientsFructans are linear or branched polymers of fructose derived from sucrose, containing one internal or terminal glucose. They belong to the broader category of non-digestible carbohydrates and are classified as soluble dietary fibers. The name "fructan" is the collective term for all such fructose-based polymers, and the individual structural classes have distinct names that reflect their linkage chemistry and botanical distribution.
They are classified into five structurally different classes depending on the trisaccharide that originates them, the glycosidic linkages between the fructose units, and the presence of branching: inulin, a linear molecule with β(2,1) linkages based on the trisaccharide 1-kestose, occurs mainly in eudicot species; phlean or levan, a linear molecule with β(2,6) linkages based on 6-kestose; graminan, a branched molecule with β(2,6) and β(2,1) linkages; the neoseries of inulin with β(2,1) linkages; and the neoseries of levan with β(2,6) linkages, both based on neokestose with an internal glucose.
Fructans also differ from one another by their degree of polymerization (DP), the smallest being the trisaccharides (DP3) and the largest reaching DP 50 in Asteraceae and DP 300 in Poaceae. Several bacteria can produce fructans with a DP of 5000 or greater, while low DP fructans (DP 3 to 200) are found in over 40,000 plant species.
The principal fructan types encountered in human nutrition and commerce are:
In contrast to the high molecular weight of fructan (levan, 1–5 × 106 Da) elaborated as an extracellular polysaccharide by some bacteria, plant fructans are much smaller by 2–3 orders of magnitude.
Inulin is innately found in over 36,000 plant species; however, it is primarily abundant in chicory root, dahlia, and Jerusalem artichoke. It is an important storage carbohydrate found in approximately 15% of flowering plant species.
Major botanical sources by plant family include:
Additional significant plant sources include garlic (Allium sativum), dandelion (Taraxacum officinale), yacon (Smallanthus sonchifolius), burdock (Arctium lappa), jicama (Pachyrhizus erosus), elecampane (Inula helenium), dahlia (Dahlia spp.), salsify, scorzonera, and banana (Musa spp.). Inulin has been part of the human diet for hundreds of years as it is contained in many fruits and vegetables such as bananas, onions, and wheat.
In addition to plants, levan is a natural polymer produced by dozens of bacterial species as well as some plants.
Fructooligosaccharides (FOS) and inulin are the most used fructans in food manufacturing, including bakery, dairy, meat products, and beverages. The main commercial forms available as dietary supplements and functional food ingredients include:
On ingredient lists, fructan-containing preparations may appear under the names inulin, chicory root fiber, chicory root extract, oligofructose, or fructooligosaccharides (FOS).
Regarding regulatory status, inulin has been recognized by the FDA as a Generally Recognized As Safe (GRAS) ingredient since 1992. Inulin sourced from agave, artichoke, and chicory is Generally Recognized As Safe (GRAS) by the United States FDA for use as a general-purpose food ingredient, bulking agent, and sweetener.
Although fructan was not isolated or characterized as a compound until the modern era, humans have consumed fructan-rich plant foods for millennia across multiple cultures.
In Mesoamerica, humans have considered the importance of agave since at least 9,000 years ago. Indigenous people gradually selected the sweetest agaves and cooked the plants inside earth holes having a bed of basalt rocks and stored them for future use. Mexican indigenous civilizations described 14 different kinds of agave. The quotidian consumption of fructans present in maguey (flowering stalk, leaves, and stem) is prehistoric, since they were the principally used plants by the first settlers of arid North America.
Some agaves were used for curing ataxia; other agaves were used to reestablish the health in women, especially after delivery and for treating articulation pains. Agave leaves were also used for preventing scurvy and for the healing of injuries. The main use was for the elaboration of alcoholic beverages such as pulque, mezcal, bacanora, and tequila. Agave fructans (agavins) are considered functional components of traditional products such as aguamiel and pulque.
Chicory (Cichorium intybus) has been cultivated and consumed in Europe since antiquity. Its roots, leaves, and shoots were used as food and in folk medicine across Mediterranean and northern European cultures. Jerusalem artichoke (Helianthus tuberosus), native to North America, was consumed by many Indigenous North American peoples as a food staple and was introduced to European cultivation in the early 17th century, where it was widely eaten as a root vegetable. In both cases, the consumption was of the whole plant food; the fructan content was not recognized at the time. There is no documented traditional medicinal use of isolated FOS as a focused therapy; instead, humans consumed FOS-containing plants as part of diets for centuries. These plant foods were used historically for food and folk medicine, but the isolated compound or nutraceutical is a modern development.
The polysaccharide "inulin" was first isolated from Inula helenium (elecampane) by the German chemist Rose in 1804, giving the compound its name. The broader class term "fructan" emerged in the 20th century as the family of related polymers was characterized more fully. The commercial extraction of inulin from chicory for use as a food ingredient began in Belgium and the Netherlands during the late 20th century and expanded rapidly from the 1990s onward.
Regardless of size, fructose polymers are not metabolized by humans and animals. Fructans, or long chains of fructose units, are resistant to human digestive enzyme hydrolysis and transit intact to the small intestine and colon where they undergo rapid fermentation by intestinal microbes. This non-digestibility is the fundamental property underpinning all observed physiological effects.
Inulin-type fructans (ITF), including short-chain fructooligosaccharides (scFOS), oligofructose, and inulin, are commonly used fibers that are widely regarded as prebiotic for their ability to be selectively utilized by the intestinal microbiota to confer a health benefit. Evidence from human clinical trials suggests that ITF have a prebiotic effect on the intestinal microbiota, promoting the abundances of Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii. For prebiotics, glucans and fructans are well proven, and evidence is building on the prebiotic effects of other substances.
Prebiotics such as inulin and FOS serve as a substrate for beneficial gut microbiota, which in turn produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. Short-chain fatty acids are mainly produced by gut microbiome fermentation of dietary fiber. Acetate, propionate, and butyrate are the three major SCFAs, and their bioactivities have been widely studied; these include anti-inflammatory, immunoregulatory, anti-obesity, anti-diabetes, anticancer, cardiovascular protective, hepatoprotective, and neuroprotective activities.
SCFAs act as a link between the microbiota and the immune system by modulating different aspects of intestinal epithelial cells (IECs) and leukocyte development, survival, and function through activation of G protein-coupled receptors (FFAR2, FFAR3, GPR109a, and Olfr78) and by modulation of the activity of enzymes and transcription factors including histone acetyltransferase and deacetylase and the hypoxia-inducible factor.
In addition to their role in digestive function, prebiotics exert direct immunomodulatory effects on the gut mucosa. Acting as dietary ligands for gut-associated lymphoid tissues, they prime both innate and adaptive immune responses, leading to enhanced frontline defense. β(2,1) fructan increases fecal secretory IgA (sIgA), a key first-line antibody defense, and enhances the expression of pathogen-sensing receptors (TLR2/4) on immune cells.
SCFAs exhibit anti-inflammatory activity; the main mechanisms of action include inhibiting the production of pro-inflammatory mediators such as IL-6 and TNF-α, as well as enhancing the production of anti-inflammatory mediators such as IL-10, TGF-β, and annexin A1.
Fermentation of fructans by colonic bacteria produces SCFAs that lower luminal pH. An acidified colon inhibits the growth of pH-sensitive pathogenic bacteria and enhances the solubility of minerals such as calcium, contributing to their increased absorption. Butyrate, the predominant SCFA energy source for colonocytes, has established roles in maintaining epithelial integrity and supporting tight-junction protein expression, thus influencing intestinal barrier function — an effect reflected in clinical data noting improved intestinal barrier function following ITF intake.
SCFA produced by beneficial gut microbiota can interact with receptors on enteroendocrine cells to promote indirect signaling to the brain via systemic circulation or through vagal pathways by stimulating the secretion of gut hormones such as glucagon-like peptide (GLP)-1 and peptide tyrosine–tyrosine (PYY), which regulate appetite and energy metabolism.
Inulin synthesis is initiated by sucrose:sucrose 1-fructosyltransferase (1-SST; EC 2.4.1.99) which catalyzes the conversion of sucrose into 1-kestose and glucose. Additional fructosyl units are added onto 1-kestose by the action of fructan:fructan 1-fructosyltransferase (1-FFT, EC 2.4.1.100), resulting in a β(2,1)-linked fructose oligomer. Levans are synthesized by a sucrose:fructan 6-fructosyltransferase (6-SFT; EC 2.4.1.10) that uses sucrose as a fructosyl donor and acceptor to produce 6-kestose.
Evidence strength: Strong for bifidogenic effect; moderate for functional digestive outcomes.
Evidence from studies included in a systematic review suggests that ITF have a prebiotic effect on the intestinal microbiota, promoting the abundances of Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii.
Fecal samples collected during a double-blind, randomized, crossover intervention study assessing the effect of inulin consumption on stool frequency in healthy adults with mild constipation were analyzed. While fecal metabolite profiles were not significantly altered by inulin consumption, analyses did detect a modest effect on global microbiota composition, and specific inulin-induced changes in relative abundances of Anaerostipes, Bilophila, and Bifidobacterium were identified. The observed decrease in Bilophila abundances following inulin consumption was associated with both softer stools and a favorable change in constipation-specific quality-of-life measures.
There was substantial variation in terms of magnitude of response and in individual responses to a specific fiber, which may be due to numerous factors such as initial presence and relative abundance of a microbial type, diet, genetics of the host, and intervention parameters such as duration and fiber dose. Fructans only occasionally decreased relative abundance of Bacteroidetes or stimulated other microbial groups.
Beneficial health effects reported following ITF intake include improved intestinal barrier function and improved laxation. Although there is some evidence for differing effects of ITF based on chain length, the lack of direct comparisons and detailed descriptions of physicochemical properties limits the ability to draw conclusions from human clinical studies.
Evidence strength: Moderate-to-strong for people with prediabetes and type 2 diabetes; weak for healthy or overweight populations.
A GRADE-assessed meta-analysis of 33 randomized controlled trials (RCTs) involving 1,346 participants found that overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), and homeostasis model assessment–insulin resistance (HOMA-IR).
In the prediabetes and type 2 diabetes population, a more significant reduction in FBG (weighted mean difference: −0.60 mmol/L; 95% CI: −0.71, −0.48 mmol/L), HbA1c (WMD: −0.58%; 95% CI: −0.83, −0.32%), fasting insulin (WMD: −1.75 µU/mL), and HOMA-IR (WMD: −0.69) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended.
A second meta-analysis of 33 RCTs reached a more nuanced conclusion: significant effects of ITF intake were observed only in diabetics, but not in other subject groups. Specifically, ITF intervention significantly decreased the weighted mean difference of blood glucose (−0.42 mmol/L; 95% CI: −0.71, −0.14; p = .004), total cholesterol (−0.46 mmol/L; 95% CI: −0.75, −0.17; p = .002), and triglycerides (−0.21 mmol/L; 95% CI: −0.37, −0.05; p = .01) compared with the control.
Analyses confirmed that four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population, and evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Importantly, effect sizes are modest and these meta-analyses carry limitations including heterogeneity in populations, doses, and ITF types used across trials.
Evidence strength: Moderate for calcium absorption enhancement in adolescents and postmenopausal women; limited for long-term bone density outcomes.
Short-term studies in adolescents have generally shown an enhancement of calcium absorption by ITF, though results have been inconsistent, and at the time of one study no studies had determined whether this effect persisted with long-term use. That study assessed the effects on calcium absorption and bone mineral accretion after 8 weeks and 1 year of supplementation with an inulin-type fructan in pubertal adolescents randomly assigned to receive 8 g/d of a mixed short- and long-chain degree of polymerization inulin-type fructan product or maltodextrin placebo.
Calcium absorption was significantly greater in the fructan group than in the control group at 8 weeks (difference: 8.5 ± 1.6%; P < 0.001) and at 1 year (difference: 5.9 ± 2.8%; P = 0.04). After 1 year, the fructan group had a greater increment in both whole-body bone mineral content (difference: 35 ± 16 g; P = 0.03) and whole-body bone mineral density (difference: 0.015 ± 0.004 g/cm²; P = 0.01) than the control group. Daily consumption of a combination of prebiotic short- and long-chain ITF significantly increased calcium absorption and enhanced bone mineralization during pubertal growth.
A 6-week study using 10 g/day of both short- and long-chain inulin-type fructans observed significant increases in calcium and magnesium absorption among postmenopausal women.
The mechanism is at least partially colonic: calcium absorption efficiency and bone mineral mass are increased in adolescents who regularly consume ITF. The mechanism of action in increasing absorption is unknown but may be related to increased colonic calcium absorption. Eight young adults (of 13 studied) with mean calcium intake approximately 900 mg/day responded to ITF with an increased calcium absorption of at least 3%.
Non-digestible oligosaccharides have been shown to increase the absorption of several minerals, including calcium, magnesium, and in some cases phosphorus, and trace elements (mainly copper, iron, zinc). The stimulation of absorption was more pronounced when the demand for calcium was high, i.e., in animals in the rapid growing stage and in animals with impaired calcium absorption. Even a small stimulation of calcium absorption increased mineral accumulation in the skeleton because of its persisting effect over months. These animal data support plausible mechanisms, but direct evidence in humans for long-term prevention of osteoporosis remains limited.
Evidence strength: Moderate for appetite hormone modulation; weak-to-moderate and inconsistent for clinically meaningful weight reduction.
The proposed mechanisms for weight management effects include decreasing hunger and increasing subjective ratings of fullness and satiety, enhancing the production and secretion of gut satiety hormones including PYY and less consistently GLP-1, and suppressing orexigenic hormones such as ghrelin.
When looking at a higher dose, 21 g/day of ITFs for 12 weeks resulted in reduced body weight and reduced self-reported energy intake coupled with a positive impact on plasma satiety hormones. In a pilot study, a 2-week treatment with 16 g/d oligofructose was shown to promote satiety following breakfast and dinner, and to reduce hunger and prospective food consumption following dinner. Total energy intake per day was 5% lower during the oligofructose treatment than during the control treatment.
However, results are not uniform. One randomized controlled crossover trial observed no effect of inulin-type fructans on appetite hormones, subjective feeling of appetite, or energy intake in patients with type 2 diabetes. Based on the results from one meta-analysis, it appeared that the beneficial effects of ITF intake were not associated with weight loss, which is probably due to the fact that most studies did not include restricted energy intake through diet or intention to lose weight as one of the factors in their data analysis.
Evidence strength: Moderate in diabetic populations; inconsistent in healthy or overweight individuals.
Beneficial health effects reported following ITF intake include decreased triglycerides and an improved lipid profile. The meta-analysis by Li et al. (2021) found that among diabetics specifically, ITF intervention significantly decreased blood glucose, total cholesterol, and triglycerides; the stability of these favorable effects was confirmed by sensitivity analysis. ITF also tends to lower LDL cholesterol (p = .084), but body weight and blood insulin were not affected.
Evidence strength: Preliminary in humans; mechanistic data are robust at the in vitro and animal level.
Human clinical trials have revealed several effects of fructan supplementation on health, including positive influence on immune function. Current evidence indicates that beneficial bacteria reduce the risk of diseases through diverse mechanisms, including modulation of gut microbiota composition or function, and regulation of host epithelial and immunological responses. Bacterial metabolism can confer advantageous effects including the production of vitamins, modulation of the immune system, enhancement of digestion and absorption, inhibition of harmful bacterial species, and removal of carcinogens and other toxins.
A growing body of evidence suggests that SCFAs (produced from fructan fermentation) regulate immunity and suppress or promote inflammatory responses in the gut and other organs. SCFAs act on a variety of cell types to regulate important biological processes, including host metabolism, intestinal function, and immune function.
Evidence strength: Moderate.
Inulin and FOS have demonstrated dose-dependent laxation effects in clinical trials, increasing stool frequency and improving stool consistency by drawing water into the colon and providing bulk through microbial biomass. The double-blind crossover study of adults with mild constipation described above provides clinical support; however, the effect size varies considerably between individuals. Improved laxation is among the beneficial health effects reported following ITF intake.
The following doses are reported as used in the cited human clinical studies and should not be interpreted as recommendations:
These dietary fibers encompass a wide range of compounds with different molecular sizes, implying a great variety of technological properties depending on the food application of interest. Dose-response relationships may differ between inulin chain lengths, individual microbiome composition, and health status of the study population.
The most commonly reported adverse effects of inulin supplementation are gas, bloating, abdominal discomfort, and altered stool consistency. These are dose-dependent and most pronounced during the first one to two weeks of supplementation. With gradual dose titration, starting at 2–3 g/day and increasing over several weeks, symptoms typically attenuate as the microbiome adapts.
Human studies lasting up to three months at doses of 10 to 20 grams per day show a consistent pattern: mild gastrointestinal symptoms are common, but no serious adverse events have been reported.
Microbial metabolism of fructans produces gas and other fermentation byproducts that can lead to excess gastrointestinal symptoms like abdominal bloating, cramping, stomach rumbling, and flatulence, especially in individuals with irritable bowel syndrome.
Inulin is classified as a high-FODMAP ingredient. It falls within the "oligosaccharide" group, specifically as a fructan. Fructans are chains of fructose molecules that are poorly absorbed in the small intestine, making them highly fermentable. Consequently, inulin is typically restricted or completely eliminated during the initial elimination phase of a low-FODMAP diet.
A randomized FODMAP reintroduction trial in IBS patients identified fructans among the most likely symptom triggers. For individuals diagnosed with irritable bowel syndrome (IBS) or those following a low-FODMAP elimination diet, even small doses (1–2 g) can trigger bloating, pain, and altered bowel habits.
A subset of the population cannot absorb fructose efficiently. Since inulin is composed of fructose chains, fermentation produces disproportionately intense gas and osmotic diarrhea in these individuals.
In SIBO, bacteria overgrow in the small intestine — upstream of the colon where fermentation is supposed to occur. Adding a fermentable substrate like inulin can worsen symptoms including distension, brain fog, and fatigue.
People with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, face a distinct concern. The fermentation and gas production that are merely uncomfortable for healthy people can aggravate inflammation and cause more serious flare-ups in IBD patients.
Allergic reactions to inulin are rare but documented. Individuals with known allergies to plants in the Asteraceae family (e.g., ragweed, chrysanthemum, daisy) may have cross-reactive sensitivity to chicory-derived inulin, though this has not been systematically quantified in large clinical studies.
While inulin is highly resistant to digestive enzymes, the glycosidic bonds of inulin are sensitive to processing by acid or heat. Dry heating of inulin (60 minutes, at 135°C and 195°C) results in significant degradation of the fructan, ranging from 20 to 100%. This is practically relevant when evaluating the fructan content of baked or heat-processed food products.
Research is ongoing into enzymatic supplements designed to hydrolyze dietary fructans in sensitive individuals. Fructanase (also known as inulinase, fructan hydrolase, beta-fructosidase) represents an approach to hydrolyze dietary fructans and improve fructan-type FODMAP tolerance. In vitro work has shown that a microbial fructanase obtained by fermentation of Aspergillus tubingensis effectively hydrolyzes a variety of dietary inulins and fructans following simulated oro-gastric digestion. A randomized controlled trial demonstrated that microbial inulinase supplementation showed a favorable safety profile in healthy adults, and further investigation in individuals with dietary FODMAP, fructan, or inulin sensitivity or IBS is warranted.
No well-characterized pharmacokinetic drug interactions with fructan-type prebiotics have been identified in authoritative clinical literature at conventional dietary supplement doses. The primary interaction of clinical note is with the gut microbiome itself: the prebiotic effect of fructans may be attenuated or modified during and after antibiotic therapy, since the bifidogenic bacteria targeted by fructans are sensitive to many common antibiotics. Inulin-type fructans stimulated mineral absorption and bone mineral accretion when combined with probiotic lactobacilli and in the presence of antibiotics, suggesting that the microbiome context modulates fructan responses. Additionally, because fructans can modulate glucose homeostasis, individuals taking antidiabetic medications should be aware of possible additive effects, though this has not been formally quantified in drug interaction studies.
Health conditions that Fructan may help support.
Body systems that Fructan may help support.
Go back